Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (65)	11/15/1999 11:58:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 447

<<''OSI's collaboration with Sankyo provides another validation of our broad- based R&D platform, bringing together independent approaches that can target distinct molecular mechanisms involved in the disease process,'' commented Colin Goddard, Ph.D., President and Chief Executive Officer of OSI Pharmaceuticals, Inc. ''OSI is continuing to build our business as a Pharmaceutical Research Organization and this renewal further validates our ability to work effectively as the Pharmaceutical industry's discovery partner.''>> Many times I asked myself: "Are OSIP scientists and middle-managements capable to continue R&D business?" If this is a way they want to continue, than there is no place for average man. Hope, PFE and Sankyo are as correct as they are confident. Miljenko